Adjunctive Treatment of Hyperuricemia with Lacticaseibacillus paracasei

INTERVENTION: Control Group:Placebo Intervention;Experimental Group (Probiotic Intervention Group):Probiotic Intervention; CONDITION: hyperuricemia PRIMARY OUTCOME: Change in serum uric acid levels from baseline to the end of treatment.; SECONDARY OUTCOME: inflammatory and oxidative stress biomarkers;liver and kidney function parameters;clinical symptoms and quality of life (the number of acute gout attacks);Proportion of participants achieving the target serum uric acid level;changes in metabolic parameters (lipid profile and blood glucose);gut microbiota composition; INCLUSION CRITERIA: 1.Aged 18–65 years, regardless of sex. 2.Meeting the diagnostic criteria for hyperuricemia: serum uric acid levels exceeding the physiological saturation threshold, defined as >420 µmol/L (7 mg/dL) in men and postmenopausal women, and >360 µmol/L (6 mg/dL) in premenopausal women. 3.Disease status and medical history: patients with or without a history of gout are eligible. Patients with a history of gout must not be experiencing an acute gout attack at enrollment, and more than 2 weeks must have elapsed since the last acute attack. 4.No use of antibiotics, live microbial preparations, or other microbiota‐modulating products within 1 month before enrollment. 5.No history of gastrointestinal or cardiovascular diseases, and no abnormalities in liver or kidney function. 6.Provide signed informed consent.